Diagnostic

Fortis Healthcare gets CCI nod to acquire stake in Agilus Diagnostics

The competition watchdog CCI on Tuesday approved Fortis Healthcare's proposal to acquire an additional 31.52 per cent stake in Agilus Diagnostics. Multi-speciality hospital chain Fortis Healthcare Ltd (FHL) is engaged in providing integrated healthcare delivery services like medicare, healthcare and diagnostics. The diagnostics services business of FHL is being undertaken primarily through Agilus. "Commission approves the acquisition of additional 31.52 per cent share capital of Agilus Diagnostics Ltd by Fortis Healthcare Ltd," according to a post by CCI on X. After the transaction, the shareholding of Fortis Healthcare Ltd (FHL) in Agilus will increase from 57.68 per cent to 89.2 per cent. In August, Fortis Healthcare announced that it will acquire a 31 per cent stake in Agilus Diagnostics for Rs 1,780 crore valuing Agilus at Rs 5,700 crore. The Competition Commission of India (CCI) has also cleared the proposed merger of Diliigent Power into DB Power, and the reorganisation of

Gradual volume growth, valuations to cap diagnostic majors' returns

Easing of pressure from predatory pricing and steady network expansion is boosting growth for diagnostics companies, say Abdulkader Puranwala and Nisha Shetty of ICICI Securities

Diagnostic Companies poised for 10-11% revenue growth in FY25: CRISIL

The projected rise in revenue comes on the back of an estimated 8% growth in FY24

Agilus Diagnostics signs agreement with SEAS to start services in Oman

The participation aims to add to the diagnostic service provider's international portfolio. Its international network consists of several centres and pick-up points (PUPs) across multiple locations

Preventive and wellness tests drive growth for diagnostic companies

Covid-19 led to increase in self-testing awareness, particularly about preventive and wellness services

Parkinson's may be detectable 20-30 years before diagnosis: Researchers

It may be possible to detect signs of Parkinson's disease 20-30 years before symptoms appear, according to researchers in Australia. A biomarker called F-AV-133, used in combination with PET, or positron emission tomography, scans can help diagnose Parkinson's disease and accurately track neurodegeneration, the researchers from the Florey Institute of Neuroscience and Mental Health, Melbourne, said. F-AV-133 is an imaging agent and has shown promise as a PET tracer for detecting and monitoring neurodegeneration in Parkinson's disease, a progressive neurological disorder characterised by tremor and impaired muscular coordination. According to the researchers, the disease, often thought of as an illness of old age, in fact, starts in midlife and can go undetected for decades. "Parkinson's disease is very hard to diagnose until symptoms are obvious, by which time up to 85 per cent of the brain's neurons that control motor coordination have been destroyed. At that point, many treatment

Hospital held liable for acting without consent

Dilip filed a complaint before the Delhi State Commission, alleging that the RFA procedure was carried out without his knowledge or consent, and also without considering the findings of the EPS

How AI is changing the diagnostic landscape, slowly but steadily

Med-tech companies are working round the clock to come up with AI-based solutions

Cipla launches diagnostic device, says it will provide results in minutes

Cippoint offers parameters to test for cardiac markers, diabetes, infectious diseases, fertility

Mylab, firm that makes kits to detect Covid, starts pathology test facility

"We are now getting to 'wet' pathology tests like blood tests etc and we have set up a centre which will have minimal human intervention and maximum automation

Torrent Pharma expected to enter diagnostics space in next 2-3 months

A company called Torrent Diagnostics Private Ltd was incorporated in February this year and has a Torrent Pharmaceuticals executive director as one of its directors

Promoters have no intention to exit business: Metropolis Healthcare

Promoters are focused on strengthening the Metropolis brand, although it continuously keeps exploring various strategic options/investment opportunities

We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD

Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country

Lupin to set up 100 diagnostic labs and 1,000 collection centres in 5 yrs

Announced foray into fragmented diagnostic business where organised chains have less than 20% share of overall business

Plasma diagnostic lab in Patna involved in selling fake RTPCR reports

Patna police have raided a plasma diagnostic lab and seized a large number of fake RT-PCR Covid-19 reports, police said.

Neuberg Diagnostics says will cross Rs 1,000 cr revenue milestone in FY22

The company is planning to set up 10 more labs in the northern and eastern parts of the country for deeper penetration

Covid-19 will drive revenues for hospitals, diagnostic labs in 2021

The RT-PCR tests will carry on, and the massive vaccination drive will require lakhs of antibody tests to check for immunity

Hope rally in diagnostic stocks may fizzle on disruption in OPD services

Lower surgeries and rising costs also likely to impact earnings; valuations too are rich

Govt restricts export of diagnostic kits, apparatus, laboratory reagents

India on Wednesday reported a spike of 9,985 more COVID-19 cases in the last 24 hours, taking the country's COVID-19 count to 2,76,583, according to the Union Ministry of Health and Family Welfare

Neuberg Diagnostics starts Covid-19 testing at its Chennai laboratory

Firm will be scaling up its capacity up to 2,000-2,500 tests a day as per ICMR norms by next week